P=N/A, N=90, Recruiting, Yuzuncu Yil University | Active, not recruiting --> Recruiting

P1/2, N=12, Not yet recruiting, BioLite, Inc. | Trial completion date: Feb 2027 --> Feb 2028 | Trial primary completion date: Feb 2027 --> Feb 2028

P4, N=226, Recruiting, VA Office of Research and Development | Trial completion date: Sep 2027 --> May 2028 | Trial primary completion date: Sep 2027 --> May 2028

In contrast, RUT treatment substantially ameliorated TRM-induced lung injury by restoring antioxidant capacity, suppressing ER stress-mediated apoptosis and autophagy, and attenuating inflammatory and nitrosative responses. Overall, these findings demonstrate that RUT confers significant protection against TRM-induced pulmonary toxicity through coordinated modulation of oxidative stress, ER stress, apoptosis, autophagy, and inflammation.

P=N/A, N=60, Completed, Cairo University

Moreover, AMI suppressed the expression of PD-L1 in cells that had been exposed to or had not been exposed to radiation, whereas radiation enhanced its expression. Because AMI exhibited promising anticancer properties including an interesting, previously unknown immunomodulatory effect, it appears that its potential therapeutic should be verified in an in vivo study.

P=N/A, N=8688, Completed, London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

P1/2, N=250, Not yet recruiting, Goethe University Frankfurt

P=N/A, N=5000, Completed, London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

P2, N=190, Recruiting, University of Rochester | Not yet recruiting --> Recruiting

P4, N=40, Recruiting, University of California, Irvine | N=100 --> 40 | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2026 --> Dec 2027

P3, N=315, Active, not recruiting, Otsuka Pharmaceutical Development & Commercialization, Inc. | Recruiting --> Active, not recruiting | Trial completion date: Oct 2027 --> Apr 2026